| Literature DB >> 35262615 |
Luísa K Pilz1,2, Natividade S Couto Pereira3,4, Ana Paula Francisco1,2, Alicia Carissimi1, Débora B Constantino1,2, Letícia B Caus3,4, Ana Carolina O Abreu1, Guilherme R Amando1,2, Fernanda S Bonatto1,2, Paula V V Carvalho5,6, José Cipolla-Neto7, Ana Harb8, Gabriela Lazzarotto3,4, Joseane Righes Marafiga3,9, Luciano Minuzzi10,11, Francisco Montagner12, Fernanda A Nishino5,6, Melissa A B Oliveira1,2, Bruno G T Dos Santos2,3, Eduardo G Steibel1, Patrice S Tavares1,13, André C Tonon1,2, Nicóli B Xavier1,2, Querusche Klippel Zanona3,4, Fernanda G Amaral5, Maria Elisa Calcagnotto2,3,4,9, Benicio N Frey10,11, Maria Paz Hidalgo1,2, Marco Idiart4,14,15, Thais Russomano16.
Abstract
OBJECTIVE: To assess the adherence to a set of evidence-based recommendations to support mental health during the coronavirus disease 2019 (COVID-19) pandemic and its association with depressive and anxiety symptoms.Entities:
Mesh:
Year: 2022 PMID: 35262615 PMCID: PMC9041970 DOI: 10.1590/1516-4446-2021-2109
Source DB: PubMed Journal: Braz J Psychiatry ISSN: 1516-4446
Summary of the main recommendations and related questions (14-day/28-day questionnaires), translated to English
| Volume/recommendation | Adherence question: Which of the following recommendations did you follow? |
|---|---|
| 1 – COVID-19 prevention | |
| Wash your hands regularly with soap or apply hand sanitizer (70% alcohol). | I washed my hands regularly or applied hand sanitizer (70% alcohol) to clean them. |
| Avoid going out; if you have to go out, wear a mask. | I avoided leaving home. |
| When outside, I wore a mask. | |
| Keep a safe distance of at least 2 m from others; if you are walking, increase the distance. | I kept a 2-m distance from other people when outside. |
| Avoid touching your eyes, nose, and mouth | I avoided touching my eyes, nose, and mouth. |
| If you need to cough or sneeze, cover your mouth and nose with the inner part of your elbow or a disposable tissue. | - |
| Stay at home if you feel sick. Viral transmission can occur at least 3 days before symptoms appear. | I stayed at home if I felt any of the COVID-19 symptoms (cough, fever, difficulty breathing...). |
| 2 – Healthy habits | |
| Avoid listening to the news all the time. | I avoided listening to the news all the time. |
| Practice body and mind relaxing techniques. | I practiced techniques to relax my mind and body. |
| Set aside some time for leisure activities. | I set aside some time for leisure activities. |
| Exercise at home. | I exercised. |
| Take care of your body posture. | I took care of my body posture. |
| Maintain good oral hygiene. | I maintained good oral hygiene. |
| Take care of your nutrition. | I was careful with my meals. |
| 3 – Biological clock and sleep | |
| Expose yourself to sunlight during the day. | I exposed myself to sunlight during the day. |
| Turn off lights at night. | I turned off lights earlier or avoided white light exposure. |
| Reduce screen time, especially at night. | I reduced the amount of screen time (computer, TV, cell phone) at night. |
| Use apps that turn your screen light yellow at night. | I used an app to change the screen color temperature to yellow at night. |
| Organize your routine according to your chronotype. | I organized my routine according to my chronotype. |
| Keep your routines regular. | I kept regular routines (sleep, meals, work-leisure). |
| Avoid long naps. | I avoided taking long naps during the day. |
| Avoid thinking about problems at bedtime. | I avoided thinking about my problems at bedtime. |
| Make your bedroom a sleep-inducing environment. | My bedroom was a sleep-inducing environment. |
| Avoid heavy meals close to bedtime. | I avoided heavy meals before bedtime. |
| Avoid caffeine and alcohol intake close to bedtime. | I avoided beverages/food containing caffeine before bedtime. |
| I avoided alcoholic beverages before bedtime. | |
| Plan your exercise schedules considering your sleep time. | I avoided doing exercise before bedtime. |
Response alternatives: 0 = never; 1 = less than half of the days; 2 = more than half of the days; 3 = every day.
COVID-19 = coronavirus disease 2019.
Participants could select not applicable (N/A) as a response to these questions.
Demographic characteristics of the study participants
| Variable | n (%) |
|---|---|
| Sex | |
| Female | 349 (85) |
| Male | 60 (15) |
| Age (years) | |
| 18-29 | 157 (38) |
| 30-45 | 179 (44) |
| 46-59 | 50 (12) |
| ≥ 60 | 23 (6) |
| Education | |
| Middle school | 1 (< 1) |
| High school | 89 (22) |
| Bachelor’s degree | 158 (39) |
| Master’s degree | 79 (19) |
| Doctoral degree | 82 (20) |
| Employment situation | |
| Formally employed | 149 (36) |
| Self-employed | 46 (11) |
| Student | 146 (36) |
| Unemployed | 21 (5) |
| Retired | 13 (3) |
| Not available | 34 (8) |
| Marital status | |
| Single | 258 (63) |
| Married | 135 (33) |
| Separated/divorced | 14 (3) |
| Widowed | 2 (< 1) |
| State of origin | |
| Bahia | 4 (1) |
| Ceará | 4 (1) |
| Minas Gerais | 14 (3) |
| Mato Grosso do Sul | 9 (2) |
| Pernambuco | 6 (1) |
| Paraná | 9 (2) |
| Rio de Janeiro | 13 (3) |
| Rio Grande do Sul | 166 (41) |
| Santa Catarina | 12 (3) |
| São Paulo | 157 (38) |
| Alagoas, Distrito Federal, Espírito Santo, Roraima | 9 (2) |
| Outside Brazil | 6 (1) |
| Geographical area | |
| Urban | 396 (97) |
| Rural | 13 (3) |
| Substance use | |
| Alcohol | 261 (64) |
| Tobacco | 20 (5) |
| Illicit drugs | 6 (1) |
| Stimulants (coffee, mate) | 301 (74) |
| Comorbidities | |
| None | 240 (59) |
| Diabetes | 7 (2) |
| Hypertension | 24 (6) |
| Asthma | 26 (6) |
| Depression | 50 (12) |
| Immunodeficiency | 5 (1) |
| Other | 104 (25) |
Recommendation adherence scores for the three volumes according to group
| Group | Volume 1
| Volume 1
| Volume 2
| Volume 2
| Volume 3
| Volume 3
|
|---|---|---|---|---|---|---|
| 1 | 86.7 (80.0-93.3) | 86.7 (80.0-93.3) | - | - | - | - |
| 2 | 86.7 (80.0-93.3) | 86.7 (80.0-93.3) | 54.8 (42.8-66.7) | 57.1 (42.9-66.7) | - | - |
| 3 | 91.1 (86.7-100.0) | 93.3 (86.7-100.0) | - | - | 65.4 (55.8-74.3) | 65.4 (51.3-73.8) |
| 4 | 88.9 (86.7-94.4) | 86.7 (80.0-93.3) | 52.4 (42.8-66.7) | 52.4 (38.1-66.7) | 61.5 (53.8-69.2) | 61.5 (52.8-71.8) |
| p-value | 0.236 | 0.211 | 0.506 | 0.542 | 0.135 | 0.570 |
Data presented as median (interquartile range) and p-values for comparison between groups.
Kruskal-Wallis test was used for Volume 1 comparisons and Wilcoxon-Mann-Whitney U test for Volumes 2 and 3 comparisons. Group 1 (control) received Volume 1; group 2 received Volumes 1 and 2; group 3 received Volumes 1 and 3; group 4 received Volumes 1, 2, and 3.
Figure 1Delta Patient Health Questionnaire-9 (PHQ-9) (A and B) and Generalized Anxiety Disorder-7 (GAD-7) (C and D) scores at the 14-day and 28-day time points, per group. Color scale represents adherence (z score) for each group. Group 1 received Volume 1; group 2 received Volumes 1 and 2; group 3 received Volumes 1 and 3; group 4 received Volumes 1, 2, and 3. Non-readers: 14 days – did not read the recommendations at 14 days; 28 days – did not read the recommendations at either 14 or 28 days.
Generalized estimating equations: adherence associated with PHQ-9/GAD-7 scores
| Model Volume 1 | Model Volume 2 | Model Volume 3 | Full | |
|---|---|---|---|---|
| Outcome: PHQ-9 scores (time point 14d/28d) | ||||
| Age (years) | -0.06 (0.01) | -0.05 (0.02) | -0.06 (0.02) | -0.05 (0.01) |
| Sex (male) | -0.01 (0.52) | 0.39 (0.68) | 0.03 (0.78) | -0.07 (0.50) |
| Initial PHQ-9 | 0.70 (0.03) | 0.63 (0.05) | 0.65 (0.05) | 0.68 (0.03) |
| Time point (28d) | -2.97 (1.95) | 2.67 (1.70) | -0.03 (1.81) | -0.26 (0.22) |
| Adherence (%) | 0.01 (0.02) | -0.05 (0.02) | -0.06 (0.03) | - |
| Adherence × time point | 0.03 (0.02) | -0.05 (0.03) | -0.00 (0.03) | - |
| Group 2 × adherence | - | - | - | -1.31 (0.54) |
| Group 3 × adherence | - | - | - | -1.31 (0.58) |
| Group 4 × adherence | - | - | - | -2.85 (0.64) |
| Outcome: GAD-7 scores (time point 14d/28d) | ||||
| Age (years) | -0.02 (0.01) | -0.02 (0.02) | -0.03 (0.02) | -0.02 (0.01) |
| Sex (male) | 0.06 (0.51) | -0.32 (0.74) | -0.14 (0.84) | -0.02 (0.50) |
| Initial GAD-7 | 0.66 (0.03) | 0.61 (0.05) | 0.60 (0.06) | 0.66 (0.03) |
| Time point (28d) | 0.41 (1.82) | 0.56 (1.04) | 2.21 (1.38) | -0.16 (0.20) |
| Adherence (%) | 0.03 (0.02) | -0.03 (0.02) | -0.02 (0.02) | - |
| Adherence × time point | 0.00 (0.02) | -0.02 (0.02) | -0.04 (0.02) | - |
| Group 2 × adherence | - | - | - | -1.02 (0.53) |
| Group 3 × adherence | - | - | - | -0.74 (0.43) |
| Group 4 × adherence | - | - | - | -1.84 (0.57) |
| n entries | n subjects | 624 | 330 | 312 | 169 | 294 | 157 | 624 | 330 |
Coefficients (standard errors). Group 1 received Volume 1; group 2 received Volumes 1 and 2; group 3 received Volumes 1 and 3; group 4 received Volumes 1, 2, and 3.
GAD-7 = Generalized Anxiety Disorder-7; PHQ-9 = Patient Health Questionnaire-9.
p < 0.05
p < 0.001.
Adherence to Volumes 1, 2, and 3 in the three first columns, respectively.
Figure 2Association between group × adherence (z score) and Patient Health Questionnaire-9 (PHQ-9) (A) or Generalized Anxiety Disorder-7 (GAD-7) (B) scores. Lines are derived from the GEE models, which included age, sex, time point, and initial PHQ-9 (A) or GAD-7 (B) scores as factors. While lines represent adherence vs. predicted score; dots show adherence vs. score. Shaded areas: 95% confidence intervals. Group 1 received Volume 1; group 2 received Volumes 1 and 2; group 3 received Volumes 1 and 3; group 4 received Volumes 1, 2, and 3.